Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026
Company Drug

GSK Halts PIVOT-PO Trial Early as Tebipenem HBr Meets Efficacy Targets for cUTI

Fineline Cube May 30, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the early termination of the pivotal Phase...

Company Drug

Amoytop Biotech Wins NMPA Approval for Weekly Inpegsomatropin in Pediatric Growth Deficiency

Fineline Cube May 30, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) announced that it has received marketing approval from...

Company Drug

Regend Therapeutics Gains NMPA Approval for Phase I/II Study of REGEND003 in Diabetes-Related CKD

Fineline Cube May 30, 2025

Suzhou-based stem cell therapy specialist Regend Therapeutics announced that it has received approval from China’s...

Company Deals

Ganzhou Hemay Pharma Files for HK IPO with SDIC Securities Sponsorship

Fineline Cube May 30, 2025

China-based Ganzhou Hemay Pharmaceutical Co., Ltd. has filed for an initial public offering (IPO) with...

Company Deals

GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation

Fineline Cube May 29, 2025

Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD...

Company Medical Device

Abbott Laboratories Receives FDA Approval for Tendyne TMVR System

Fineline Cube May 29, 2025

US-based medical device giant Abbott Laboratories (NYSE: ABT) announced that it has received marketing approval...

Company Deals

AusperBio Secures $50M in Oversubscribed Series B+ Round to Advance Hepatitis B Therapy

Fineline Cube May 29, 2025

Sino-US liver therapy developer AusperBio announced the successful closing of an oversubscribed Series B+ financing...

Company Drug

BMS Gains European Approval for Opdivo Subcutaneous Formulation

Fineline Cube May 29, 2025

Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to...

Company Drug

Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China

Fineline Cube May 29, 2025

The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical...

Company Drug

InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248

Fineline Cube May 29, 2025

Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical...

Company Deals

Fosun Pharma and Jiuyuan Gene Partner to Commercialize Biologics in Global Markets

Fineline Cube May 29, 2025

Chinese pharmaceutical firms Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Hangzhou...

Company Drug

Lupeng Pharma’s Rocbrutinib Near Approval for Mantle Cell Lymphoma

Fineline Cube May 29, 2025

Guangzhou Lupeng Pharmaceutical Co., Ltd’s rocbrutinib is currently under New Drug Application (NDA) review at...

Company Deals

Viva Biotech Establishes RMB 300M Fund for Early-Stage Pharma Projects

Fineline Cube May 29, 2025

China-based Contract Research Organization (CRO) Viva Biotech (HKG: 1873) announced that its wholly-owned subsidiary, Hangzhou...

Company Drug

Bayer’s Sevabertinib Receives FDA Priority Review for HER2-mutant NSCLC

Fineline Cube May 29, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its investigational oral small-molecule tyrosine kinase...

Company Drug

JW Therapeutics’ Carteyva Receives Fourth sBLA for r/r LBCL

Fineline Cube May 29, 2025

JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...

Company Medical Device

Sino Medical Sciences Technology’s AUCURA Flow-Diverting Stent Approved by NMPA

Fineline Cube May 29, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that its holding subsidiary Neurovita has...

Company Drug

Changchun Pharma Wins FDA Approval for GenSci128 in TP53 Y220C Solid Tumors

Fineline Cube May 29, 2025

China-based Changchun High & New Technology Industries (Group) Inc., (SHE:000661) announced that its subsidiary Changchun...

Company Drug

Yantai Dongcheng Pharma Gains NMPA Approval for Sodium Fluoride [18F]

Fineline Cube May 28, 2025

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has received marketing approval from the...

Company Deals

Guided Therapeutics Receives Payment from Shandong Yaohua for LuViva Commercialization

Fineline Cube May 28, 2025

US-based Guided Therapeutics, Inc. (OTCMKTS: GTHP), a developer of rapid, painless testing platforms based on...

Company Drug

RemeGen’s Telitacicept Approved for Myasthenia Gravis in China

Fineline Cube May 28, 2025

China-based pharmaceutical firm RemeGen (HKG: 9995) announced the third indication approval from the National Medical...

Posts pagination

1 … 143 144 145 … 656

Recent updates

  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
  • Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
  • Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
  • China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.